Morgan Stanley Rates Pharvaris (PHVS) buy, $46 Price Target
Morgan Stanley maintains its positive outlook on PHVS with a $46 price target, a 38.18% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Morgan Stanley rated Pharvaris N.V. ($PHVS) "buy" with a $46 price target on June 25, 2026.
Since the rating, $PHVS is up 1.7% after 1 week, up 2.0% after 1 month and down 16.7% to date (from the $33.30 close on Jun 25, 2026).
PHVS
Pharvaris N.V.
Key Points
- Morgan Stanley reiterated its buy rating for PHVS on June 25, 2026, with a target price of $46.
- Morgan Stanley's $46 price target implies 38.18% upside from Pharvaris N.V.'s ($PHVS) current $33.29 share price.
- PHVS shares traded near $33.29 on Thursday, reflecting market interest in the company's prospects.
- Insider transactions at PHVS included selling by the Chief Medical Officer and CEO in June 2026.
Get $PHVS trade alerts by text
We text you when insiders, Congress or big funds trade $PHVS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Pharvaris N.V. alert may contain errors. Disclosures
Morgan Stanley has reaffirmed its confidence in PHVS, maintaining a buy rating and setting a price target of $46. This move by analyst Matthew Harrison on June 25, 2026, underscores Morgan Stanley's positive outlook on the company's future performance.
Morgan Stanley vs. the S&P 500
Hypothetical returns from Morgan Stanley's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in PHVS
General Atlantic, L.P. held steady with 8,031,252 shares, valued at approximately $226.9 million. FMR LLC slightly reduced its position by 114,686 shares, ending with about 6,284,472 shares valued at $177.5 million, a 1.8% decrease. Foresite Capital Management IV, LLC maintained its holdings at 4,778,581 shares, worth $134.9 million. Venbio Partners LLC also kept its stake unchanged with 4,639,304 shares, valued at $131.1 million. Viking Global Investors LP held steady at 3,653,310 shares, with a value of $103.2 million.
Pharvaris N.V. Stock Down 8.5%
Shares of PHVS traded near $33.29 on Thursday. The stock has seen varied interest from institutional investors, as reflected in recent trading activity. Although specific market cap and P/E ratio data weren't provided, the stock's recent trading price indicates ongoing investor engagement.
$PHVS price target
Pharvaris N.V. daily closes and this analyst's $46 target. Not advice.
Insider Buying and Selling at Pharvaris N.V.
In June 2026, several insider transactions were reported at PHVS. Lu Peng, the Chief Medical Officer, sold 300 shares at $34.00 on June 18 under a planned transaction and bought 300 shares at $2.59 on the same day. Additionally, Berndt Modig, the CEO, sold 2,291 shares at an average price of $31.07 on June 15 in a planned sale. Peng also sold smaller amounts on June 12 and 11 at prices of $32.20 and $31.51, respectively.
Analysts Set New Price Targets
On June 25, 2026, Morgan Stanley maintained its buy rating for PHVS with a $46 price target. Other analysts have also shown interest: Citizens maintained a buy rating with a $74 target on May 13, 2026, and Wolfe Research initiated coverage with a buy rating and a $42 target on April 9, 2026. The consensus among analysts remains positive, with a strong buy recommendation and a mean target price reflecting optimism for PHVS's future.
Bottom Line
Morgan Stanley's reiterated buy rating for PHVS with a $46 target highlights ongoing institutional interest in the company. While insider sales were noted, these are part of planned transactions and do not necessarily indicate a negative outlook. Investors continue to watch PHVS closely, as reflected in recent analyst ratings and institutional holdings.
Related Filing Alerts
Source: Morgan Stanley's rating change on $PHVS (Jun 25, 2026). Written by software, not financial advice. How we make alerts